Nigel Burns has been appointed chairman of Cell Medica, a UK company that develops cellular immunotherapy treatment strategies for infectious disease. Dr Burns has more than 20 years of experience in the biotechnology industry including holding senior management positions at Cambridge Antibody Technology which was acquired by AstraZeneca in 2006. Previous to that he headed the process technology division at British Biotech.
Cell Medica’s lead clinical application involves the transfer of donor-derived virus-specific T cells into patients in order to prevent infections after allogeneic haematopoietic stem cell transplant.
Copyright 2008 Evernow Publishing Ltd